Loading
AN2 Therapeutics, Inc. Stock: price and insider trades · United States
1 insider bought €9,989 of shares over the last 90 days, the latest by FitzPatrick Margaret M, filed 02 Sept 2026.
AN2 Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at AN2 Therapeutics, Inc. as filed with SEC (Form 4), a company from the Health Care sector. Between 23 October 2025 and 23 October 2026, 14 insiders published 42 filings.
The record shows 1 purchase on the open market worth €9,989, made by 1 insider, against 21 sales worth €341k by 6 insiders. Taken together, the sales exceed the purchases by €331k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €97k, sold by Readnour Robin Shane and made public on 19 August 2026 (0.060% of market cap). Among those who bought: 1 senior executive.
The last insider purchase was made public on 2 September 2026, 52 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 3,167 companies tracked on its exchange, the median is 24 filings; at 42 filings, this issuer sits above that mark. Since 2022, the database holds 36 purchases and 82 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -35.2 m USD.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
220
Thresholds
n/a
Buy Volume
€44M
36 ops. · all time
Sell Volume
€14M
82 ops. · all time
Who traded when
BuySaleRobin Shane Readnour14 buys8 sales
Joshua M. Eizen5 sales
Leonard Braden Michael5 sales
Prior Stephen David4 sales
Joseph S. Zakrzewski3 buys
Sarah Joanne Williams3 sales
+4 other insiders
Since the insiders bought
- -38.8%Entry US$5.95 · Close 22 Oct 2026 US$3.64
- +282.6%Entry US$1.09 · Close at T+365 US$4.17
- -23.2%Entry US$1.55 · Close at T+365 US$1.19
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.64
Analyst consensus
2 analysts1.00/5
US$9.00Target US$9.00(+147%)US$9.00
Income statement
EBITDA-US$38.1M
Net income-US$35.2M0.0% margin
Valuation
PER (forward)-4.6x
P/Book1.7x
Beta-0.98
Balance sheet & cash
Market capUS$137.4M
Free Cash Flow-US$29.8M
Profitability & ownership
ROE-50.1%
ROA-30.8%
% insiders16.0%
% institutions76.9%
Last declaration on 13 October 2026
Declarations220 total
2,283 shares0Common StockSEC:0001193125-26-420643:0
389 shares0Common StockSEC:0001193125-26-420641:0
2,465 shares0Common StockSEC:0001193125-26-420639:0
116,667 shares0Common StockSEC:0001193125-26-393274:0
523 shares@ US$6.02430.0024% mcap0.0% of flowCommon StockSEC:0001193125-26-389545:0
585 shares@ US$6.02430.0027% mcap0.1% of flowCommon StockSEC:0001193125-26-389545:1
2,877 shares@ US$6.06980.013% mcap0.2% of flowCommon StockSEC:0001193125-26-385511:0
3,223 shares@ US$6.06980.015% mcap0.2% of flowCommon StockSEC:0001193125-26-385511:1
4,725 shares@ US$6.01830.022% mcap0.3% of flowCommon StockSEC:0001193125-26-385511:2
5,294 shares@ US$6.01830.024% mcap0.3% of flowCommon StockSEC:0001193125-26-385511:3
272 shares@ US$5.530.0008% mcap49.8% of flowCommon StockSEC:0001193125-26-383697:0
2,098 shares@ US$5.530.0062% mcap52.5% of flowCommon StockSEC:0001193125-26-380595:0
Canonical exit: 30 Nov 2026 (T+90)
16,696 shares@ US$6.00820.053% mcap1.5% of flowCommon StockSEC:0001193125-26-357225:0
18,706 shares@ US$6.00820.060% mcap1.7% of flowCommon StockSEC:0001193125-26-357225:1
1,012,000 shares@ US$6.00823.24% mcap91.4% of flowCommon StockSEC144:0001972481-26-000263
405,880 shares0Common StockSEC:0001193125-26-351801:0
2,789 shares0Common StockSEC:0001193125-26-301166:0
766 shares0Common StockSEC:0001193125-26-301165:0
2,852 shares0Common StockSEC:0001193125-26-301167:0
5,945 shares@ US$4.1720.013% mcap41.4% of flowCommon StockSEC:0001193125-26-301092:0
265 shares@ US$4.430.0006% mcap38.8% of flowCommon StockSEC:0001193125-26-253622:0
3,775 shares0Common StockSEC:0001193125-26-151628:0
3,775 shares0Common StockSEC:0001193125-26-151632:0
1,192 shares0Common StockSEC:0001193125-26-151626:0
327 shares@ US$1.0611.4% of flowCommon StockSEC:0001193125-26-094490:0
25 of 220 declarations
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for infectious diseases. The company is listed on NASDAQ under the ticker ANTX.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
